{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:26:17Z","timestamp":1789608377253,"version":"build-2803163510"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine & Growth Factor Reviews"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.cytogfr.2016.08.001","type":"journal-article","created":{"date-parts":[[2016,8,13]],"date-time":"2016-08-13T03:23:49Z","timestamp":1471058629000},"page":"83-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Understanding Interferon Subtype Therapy for Viral Infections: Harnessing the Power of the Innate Immune System."],"prefix":"10.1016","volume":"31","author":[{"given":"Cassandra M.","family":"Berry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cytogfr.2016.08.001_bib0005","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.tim.2013.04.004","article-title":"Innate immune detection of microbial nucleic acids","volume":"21","author":"G\u00fcrtler","year":"2013","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0010","doi-asserted-by":"crossref","DOI":"10.1002\/eji.201545794","article-title":"Mouse superkiller-2-like helicase DDX60 is dispensable for type I IFN induction and immunity to multiple viruses","author":"Goubau","year":"2015","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0015","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2217\/bmm.12.10","article-title":"Interferons as biomarkers and effectors: lessons learned from animal models","volume":"6","author":"Berry","year":"2012","journal-title":"Biomark Med"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0020","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nri3875","article-title":"Translating nucleic acid-sensing pathways into therapies","volume":"15","author":"Junt","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0025","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0030","doi-asserted-by":"crossref","first-page":"20047","DOI":"10.1074\/jbc.R700004200","article-title":"The interferons: 50 years after their discovery, there is much more to learn","volume":"282","author":"Petska","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0035","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cytogfr.2014.07.015","article-title":"Interferons: Success in anti-viral immunotherapy","volume":"25","author":"Lin","year":"2014","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0040","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s13238-013-3021-1","article-title":"Distinct evolution process among type I interferon in mammals","volume":"4","author":"Xu","year":"2013","journal-title":"Protein Cell"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0045","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.4049\/jimmunol.178.3.1457","article-title":"Influenza virus infection causes global respiratory tract B cell response modulation via innate immune signals","volume":"178","author":"Chang","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0050","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1084\/jem.189.4.663","article-title":"Interferons regulate the phenotype of wild-type and mutant herpes simplex viruses in vivo","volume":"189","author":"Leib","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0055","doi-asserted-by":"crossref","first-page":"6201","DOI":"10.1128\/JVI.00113-13","article-title":"Lymphoid-tissue stromal cells coordinate innate defense to cytomegalovirus","volume":"87","author":"Verma","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0060","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/978-1-4419-6676-6_18","article-title":"Identification and validation of ISG15 target proteins","volume":"54","author":"Durfee","year":"2010","journal-title":"Subcell Biochem"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0065","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/135965350801300306","article-title":"Distinct signature type I interferon responses are determined by the infecting virus and target cell","volume":"13","author":"Baig","year":"2008","journal-title":"Antivir Ther"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0070","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cytogfr.2007.06.013","article-title":"How cells respond to interferons revisited: from early history to current complexity","volume":"18","author":"Stark","year":"2011","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0075","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/hep.24580","article-title":"Sheahan TP et al: Hepatitis C. virus induced interferon-\u03bb and interferon-stimulated genes in primary liver cultures","volume":"54","author":"Marukian","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0080","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1074\/jbc.R300030200","article-title":"Inhibitors of cytokine signal transduction","volume":"279","author":"Wormald","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0085","doi-asserted-by":"crossref","first-page":"D852","DOI":"10.1093\/nar\/gkn732","article-title":"Interferome: the database of interferon regulated genes","volume":"37","author":"Samarajiwa","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0090","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nri3865","article-title":"The multifaceted biology of plasmacytoid dendritic cells","volume":"15","author":"Swiecki","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0095","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.immuni.2011.06.014","article-title":"Mapping a dynamic innate immunity protein interaction network regulating type I interferon production","volume":"35","author":"Li","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0100","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1084\/jem.20051395","article-title":"Production of type I interferons: plasmacytoid dendritic cells and beyond","volume":"202","author":"Asselin-Paturel","year":"2009","journal-title":"J Exp Med"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0105","doi-asserted-by":"crossref","first-page":"11534","DOI":"10.1128\/JVI.01727-15","article-title":"Virus multiplicity of infection affects type I interferon subtype induction profiles and interferon-stimulated genes","volume":"89","author":"Zaritsky","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.cytogfr.2016.03.006","article-title":"Brain heterogeneity leads to differential innate immune responses and modulates pathogenesis of viral infections","author":"Zegenhagen","year":"2016","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0115","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.it.2005.05.004","article-title":"Viruses know it all: new insights into IFN networks","volume":"26","author":"Hengel","year":"2005","journal-title":"Trends Immunol"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0120","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.smim.2015.03.005","article-title":"Early IFN type I response: learning from microbial evasion strategies","volume":"27","author":"Coccia","year":"2015","journal-title":"Sem Immunol"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0125","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1128\/JVI.02247-12","article-title":"Contribution of double-stranded RNA and CPSF30 binding domains of influenza virus NS1 to the inhibition of type I interferon production and activation of human dendritic cells","volume":"87","author":"Ramos","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0130","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1073\/pnas.0600007103","article-title":"A human cytomegalovirus antagonist of type I IFN-dependent signal transducers and activator of transcription signalling","volume":"103","author":"Paulua","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0135","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.virol.2006.10.028","article-title":"Recruitment of activated IRF-3 and CBP\/p300 to herpes simplex virus ICP10 nuclear foci: potential role in blocking IFN-beta induction","volume":"360","author":"Melroe","year":"2007","journal-title":"Virol"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0140","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.virol.2009.09.021","article-title":"Herpes simplex virus-1 infection causes the secretion of a type I interferon-antagonizing protein and inhibits at or before Jak-1 activation","volume":"396","author":"Johnson","year":"2010","journal-title":"Virol"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0145","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.cytogfr.2012.06.001","article-title":"HIV-1, interferon and the interferon regulatory factor system: an interplay between induction, antiviral responses and viral evasion","volume":"23","author":"Marsili","year":"2012","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0150","doi-asserted-by":"crossref","first-page":"5772","DOI":"10.4049\/jimmunol.1401541","article-title":"The plasmacytoid dendritic cell as the Swiss army knife of the immune system: molecular regulation of its multifaceted functions","volume":"193","author":"Karrich","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0155","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nm1352","article-title":"Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity","volume":"12","author":"Chan","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0160","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.gene.2015.04.087","article-title":"IFNA2: The prototypic human alpha interferon","volume":"567","author":"Paul","year":"2015","journal-title":"Gene"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0165","doi-asserted-by":"crossref","first-page":"749","DOI":"10.2165\/00003495-199142050-00003","article-title":"The use of interferon-alpha in virus infections","volume":"42","author":"Finter","year":"1991","journal-title":"Drugs"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0170","first-page":"3045","article-title":"Protection from pulmonary tissue damage associated with infection of cynomolgus macaques by highly pathogenic avian influenza virus (H5N1) by low dose natural human IFN-\u03b1 administered to the buccal mucosa","volume":"193","author":"Strayer","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0175","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1186\/1743-422X-8-525","article-title":"Oral administration of interferon-\u03b12b-transformed Bifidobacterium longum protects BALB\/c mice against coxsackievirus B3-induced myocarditis","volume":"8","author":"Yu","year":"2011","journal-title":"Virol J"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0180","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1089\/10799900152547830","article-title":"Oromucosal interferon therapy: relationship between antiviral activity and viral load","volume":"21","author":"Schellekens","year":"2001","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0185","first-page":"193","article-title":"Oral therapy with human interferon alpha in calves experimentally injected with infectious bovine rhinotracheitis virus","volume":"41","author":"Cummins","year":"1993","journal-title":"Arch Immunol Ther Exp"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0190","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.4049\/jimmunol.178.4.2182","article-title":"TLR signalling fine-tunes anti-influenza B cell responses without regulating effector T cell responses","volume":"178","author":"Heer","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0195","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1016\/j.vaccine.2006.10.038","article-title":"Differential activities of alpha\/beta IFN subtypes against influenza virus in vivo and enhancement of specific immune responses in DNA vaccinated mice expressing haemagglutinin and nucleoprotein","volume":"25","author":"James","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0200","first-page":"5670","article-title":"Interferon-\u03b2 modulates type I immunity during influenza virus infection","volume":"84","author":"Yoo","year":"2010","journal-title":"Antiviral Res"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0205","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1038\/ncomms4864","article-title":"Wack A: Pathogenic potential of interferon \u03b1\u03b2 in acute influenza infection","volume":"5","author":"Davidson","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0210","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1089\/107999099313389","article-title":"Efficacy of low-dose oral use of type I interferon in cytomegalovirus infections in vivo","volume":"19","author":"Bosio","year":"1999","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0215","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.4049\/jimmunol.160.6.2932","article-title":"Antiviral activities of individual murine IFN-\u03b1 subtypes in vivo: intramuscular injection of IFN expression constructs reduces murine cytomegalovirus replication","volume":"160","author":"Yeow","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0220","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1006\/jaut.2000.0492","article-title":"From infection to autoimmunity","volume":"16","author":"Fairweather","year":"2001","journal-title":"J Autoimmun"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0225","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1006\/cimm.2001.1859","article-title":"Immunomodulation of murine cytomegalovirus-induced myocarditis in mice treated with lipopolysaccharide and tumor necrosis factor","volume":"213","author":"Lenzo","year":"2001","journal-title":"Cell Immunol"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0230","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1046\/j.0818-9641.2004.01234.x","article-title":"gene therapy suppresses cardiac CD8 Type I IFN-\u03b2+ T-cell infiltration during autoimmune myocarditis","volume":"82","author":"Bartlett","year":"2004","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0235","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1046\/j.1365-2567.2002.01423.x","article-title":"Type I interferon gene therapy protects against cytomegalovirus-induced myocarditis","volume":"106","author":"Cull","year":"2002","journal-title":"Immunol"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0240","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0166-3542(02)00093-1","article-title":"Transient transfection of mouse fibroblasts with type I interferon transgenes provides various degrees of protection against herpes simplex virus infection","volume":"56","author":"Harle","year":"2002","journal-title":"Antiviral Res"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0245","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.1128\/JVI.76.13.6558-6567.2002","article-title":"Differential effect of murine alpha\/beta interferon transgenes on antagonization of herpes simplex virus type 1 replication","volume":"76","author":"Harle","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0250","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1251\/bpo118","article-title":"Direct application of plasmid DNA containing type I interferon transgenes to vaginal mucosa inhibits HSV-2 mediated mortality","volume":"8","author":"Austin","year":"2006","journal-title":"Biol Proced Online"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0255","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.4049\/jimmunol.175.2.1100","article-title":"Critical role for the oligoadenylate synthetase\/RNaseL pathway in response to IFN-\u03b2 during acute ocular herpes simplex virus type 1 infection","volume":"175","author":"Austin","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0260","first-page":"136","article-title":"Anti-retroviral effects of type I IFN subtypes in vivo","volume":"39","author":"Gerlach","year":"2009","journal-title":"Retrovirol"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0265","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/nrmicro3449","article-title":"HIV-1 and interferons: who\u2019s interfering with whom?","volume":"13","author":"Doyle","year":"2015","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0270","doi-asserted-by":"crossref","first-page":"6001","DOI":"10.1128\/JVI.00451-16","article-title":"Interferon alpha subtype-specific suppression of HIV-1 infection in vivo","volume":"90","author":"Lavender","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005254","article-title":"Interferon-\u03b1 subtypes in an ex vivo model of acute HIV -1 infection: expression potency and effector mechanisms","author":"Harper","year":"2015","journal-title":"PLoS Pathogens"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0280","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/B978-0-12-407707-2.00002-3","article-title":"Residual immune dysregulation syndrome in treated HIV infection","volume":"119","author":"Lederman","year":"2013","journal-title":"Adv Immunol"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0285","article-title":"Immune activation in the course of HIV-1 infection: Causes, phenotypes and persistence under therapy","author":"Younas","year":"2015","journal-title":"HIV Med"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0290","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115226","article-title":"Elevated plasma soluble CD14 and skewed CD16+ monocyte distribution persist despite normalisation of soluble CD163 and CXCL10 by effective HIV therapy: a changing paradigm for routine HIV laboratory monitoring?","author":"Castley","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158169","article-title":"Plasma CXCL10, sCD163 and sCD14 levels have distinct associations and antiretroviral treatments and cardiovascular disease risk factors","author":"Castley","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0300","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1128\/AAC.02427-15","article-title":"Antiviral activities of different interferon types and subtypes against hepatitis E virus replication","volume":"60","author":"Todt","year":"2016","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0305","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1743-422X-6-70","article-title":"Enhanced anti-HCV activity of interferon alpha 17 subtype","volume":"6","author":"Dubois","year":"2009","journal-title":"Virol"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0310","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jaci.2013.06.006","article-title":"Viral infection of the lung: host response and sequelae","volume":"132","author":"Yoo","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0315","doi-asserted-by":"crossref","first-page":"25","DOI":"10.12703\/P6-25","article-title":"Learning from myocarditis: mimicry, chaos and black holes","volume":"6","author":"Rose","year":"2014","journal-title":"F1000Prime Rep"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0320","doi-asserted-by":"crossref","first-page":"e1001139","DOI":"10.1371\/journal.ppat.1001139","article-title":"Viral replication rate regulates clinical outcome and CD8T cell responses during highly pathogenic H5N1 influenza virus infection in mice","volume":"6","author":"Hatta","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0325","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2174\/1874467210902010032","article-title":"Antiviral strategies: the present and beyond","volume":"2","author":"Burke","year":"2009","journal-title":"Curr Mol Pharmacol"},{"key":"10.1016\/j.cytogfr.2016.08.001_bib0330","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3390\/cells3020438","article-title":"HSV-1 ICP0: An E3 ubiquitin ligase that counteracts host intrinsic and innate immunity","volume":"3","author":"Lanfranca","year":"2014","journal-title":"Cells"}],"container-title":["Cytokine & Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610116300909?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610116300909?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T13:23:28Z","timestamp":1692451408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610116300909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":66,"alternative-id":["S1359610116300909"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2016.08.001","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding Interferon Subtype Therapy for Viral Infections: Harnessing the Power of the Innate Immune System.","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2016.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}